Lidocaïne Hcl B. Braun (Lidocaine Hydrochloride Monohydrate)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state. This prevents the initiation and propagation of action potentials, thereby halting nerve impulse transmission and producing a localized anesthetic effect without affecting surrounding tissues.

The specific dose of Lidocaïne Hcl B. Braun is determined by the prescribing clinician based on the intended procedure, patient weight, age, and clinical condition. Healthcare professionals calculate the appropriate amount to achieve effective anesthesia while minimizing toxicity.

Safety data for lidocaine in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the prescriber. Lidocaine does pass into breast milk in small amounts, so caution is advised for nursing mothers.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lidocaine offers a rapid onset (1–3 minutes) and moderate duration (1–2 hours) compared with agents such as bupivacaine, which has a slower onset but longer duration. Its safety profile is well‑characterised, and it is frequently chosen for procedures requiring quick, reliable anesthesia and for diagnostic testing.

Lidocaïne Hcl B. Braun should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture and extreme temperatures to maintain sterility and potency.

The product is supplied as a sterile injectable solution and is administered by a qualified healthcare professional via epidural, intradermal or intramuscular injection, following aseptic technique and appropriate dosing guidelines for the specific indication.

Serious risks include systemic toxicity manifesting as central nervous system symptoms (e.g., seizures) or cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and rare cases of methemoglobinemia. Prompt recognition and management are essential if these events occur.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe heart block, or individuals receiving class I antiarrhythmic drugs should avoid this product unless a prescriber determines that benefits outweigh risks.